Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Loxo Sees Larotrectinib As Model Form Of Oncology Drug Development

Jun 05 2017

• By Mary Jo Laffler

Related Content

Puma's Neratinib SUMMIT Study Shows Potential & Pitfalls Of Precision Medicine

Apr 03 2017

Biomarker-Led Claim Is Small Step For Merck's Keytruda, Giant Leap For Cancer Indications

May 23 2017

Oncology: Tissue-Agnostic Indications Advance Under US FDA's Breakthrough Umbrella

May 26 2017

Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice

Jun 05 2017

Tissue-Agnostic Approach To Cancer Drug Development Takes A Hit

Sep 14 2015

Genomics-Driven Trials Built To Be Fast And Flexible

Sep 21 2015

Thermo Fisher Makes Final Push For ‘Universal’ Lung-Cancer Companion Dx

Nov 14 2016

Related Companies

Loxo Oncology at Lilly

Merck & Co., Inc.

Ignyta, Inc.

Foundation Medicine, Inc.

Thermo Fisher Scientific

Roche Holding AG

Ventana Medical Systems, Inc.

Novartis AG

Puma Biotechnology, Inc.

Additional Topics

Clinical Trials Review Pathway Regulation Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window